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OBJECTIVE: The objective of this study was to investigate mdm2 (murine double minute 2) protein expression and evaluate its 
relationship with some anatomical and pathological aspects, aiming also to identify prognostic factors concerning local recurrence-
free survival, metastasis-free survival and overall survival in patients with primary liposarcomas of the extremities.
MATERIALS AND METHODS: Of 50 patients with primary liposarcomas of the extremities admitted to a Reference Service, 
between 1968 and 2004, 25 were enrolled in the study, following eligibility and exclusion criteria. 
RESULTS: The adverse factors that influenced the risk for local recurrence in the univariant analysis included male sex (P = 0.023), 
pleomorphic histological subtype (P = 0.027), and high histological grade (P = 0.007). Concerning metastasis-free survival, age 
less than 50 years (P = 0.040), male sex (P = 0.040), pleomorphic subtype (P < 0.001), and high histological grade (P = 0.003) had 
a worse prognosis. Adverse factors for overall survival were age under 50 years (P = 0.040), male sex (P = 0.040), pleomorphic 
subtype (P < 0.001), and high histological grade (P = 0.003).
CONCLUSIONS: There was no correlation between immunohistochemically observed mdm2 protein expressions and the 
anatomical and pathological variables studied. The immunohistochemical expression of mdm2 protein was not considered 
to have a prognostic value for any of the surviving patients in this study (local recurrence-free survival, metastasis-free 
survival, or overall survival). The immunoexpression of mdm2 protein was a frequent event in the different subtypes of   
liposarcomas.
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INTRODUCTION
Soft tissue sarcomas are rare neoplasias; however, they 
may be present across all age groups and all body sites 
where soft tissues exist. In the United States, soft tissue 
sarcomas (STSs) occur in 0.7% of cancer patients aged 
16 years and over.1 In Brazil, the actual incidence of these 
neoplasias is difficult to determine due to lack of appropri-
ate records.
Although being rare, STSs have a relatively high 
mortality rate. This high mortality can be attributed in 
part to aggressive local invasion, but mostly to frequent   
metastases.2
Liposarcomas can occur in any anatomical site; con-
cerning the extremities, they occur more frequently in the 
thigh.3-7
Adipose tissue tumors represent a group of injuries 
whose classification is an issue of continuous debate.8,9 
Liposarcomas have been shown to possess many histologi-
cal patterns.10 Many changes have occurred over the years 
concerning the histological classification of this type of soft 
tissue sarcoma. Currently, according to the Classification of 
Soft Tissue and Bone Tumors of the World Health Organi-
zation, it is accepted that this sarcoma presents as one of 5 158
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histological subtypes: well-differentiated, dedifferentiated, 
myxoid/round-cell, pleomorphic, and mixed.11
Most frequently, the proto-oncogene mdm2 is amplified 
in soft tissue sarcomas. Most of the known oncogenes are 
changed by amplification, resulting in overexpression and, 
consequently, high levels of their protein products.
The q 13-15 region of chromosome 12 is complex and 
contains different genes, such as mdm2,12 that are amplified 
or reorganized in lipomatous tumors, which can be demon-
strated by immunohistochemistry.13,14
The number of publications on the molecular characteris-
tics of STSs is constantly increasing, and research focuses on 
the search for additional prognostic factors, aiming to iden-
tify those related to risk of local recurrence, metastases, and 
death due to the disease, and to study their correlation with 
known clinical, anatomical, and pathological variables.15
The determination of molecular variables related to ana-
tomical and pathological aspects and to the prognosis could 
help identify subgroups of patients with better or worse 
prognoses.15 Thus, with more prognostic factors identified, it 
would be possible to select the risk patients and work toward 
improved therapeutic outcomes.
The objective of this study, which is part of a general 
survey on sarcomas,16 was to investigate mdm2 protein ex-
pression and evaluate its relationship with some anatomical 
and pathological aspects, aiming also to identify prognostic 
factors concerning local recurrence-free survival, metastasis-
free survival, and overall survival in patients with primary 
liposarcomas of the extremities.
MATERIALS AND METHODS
A review was performed of the medical records of pa-
tients who were anatomically and pathologically diagnosed 
with liposarcoma of the extremities and were admitted to 
the Institute of Orthopedics and Traumatology, Faculty of 
Medicine, University of São Paulo (IOT/FMUSP), SP, Bra-
zil, between 1968 and 2004. Based on these medical records 
and after a detailed anatomical and pathological evaluation 
from the paraffin blocks of specimens obtained in the origi-
nal biopsy, we selected 50 patients. Of these 50 patients, 5 
were excluded for presenting local recurrence in the first 
evaluation, and another 3 because they underwent biopsy 
only, with no treatment. Another 17 cases were excluded 
because their follow-up periods were less than 24 months. 
The analysis of variables was then performed for 25 patients 
(and their medical records) who underwent treatment at IOT-
HC/FMUSP. The anatomical and pathological evaluation was 
made from paraffin blocks containing tumor fragments that 
were obtained from the surgical specimens.
The following variables were studied:
1. Clinical and epidemiological variables
Sex, age, and ethnicity
Of the 25 patients studied, 11 (44%) were men and 14 
(56%) were women (ratio of 1:1.27).
The mean age was 52 ±  15 years (range, 20-86 years; 
median 53). Eleven patients (44%) were aged under 50 years, 
and 14 (56%) were 50 years old or over.
Caucasians were the most affected, with 22 (88%) sub-
jects.
Anatomical site
Fifteen (60%) patients had tumor formation in the thigh. 
For the other patients, the leg was affected in 4 (16%) cases 
and the forearm in 2 (8%) cases. The arm, axilla, scapula, 
and foot were also affected (1 of each). The right side of the 
body exceeded its contralateral side in the 1.5:1 ratio.
Clinical condition and delay in seeking medical advice
The unanimous clinical complaint was the insidious on-
set of usually painless local tumors. The secondary symptom 
was pain, occurring in only 3 (12%) cases.
The period between the onset of symptoms and the seek-
ing of medical advice was 2.9 months, ranging between 2 
and 120 months (mean, 36.0 ± 41.3 months; median, 24.0 
months).
Remote metastasis
Metastasis was identified in 3 (12%) patients, 1 with 
high-grade myxoid/round-cell histology and 2 with pleomor-
phic histology. All 3 patients developed an extrapulmonary 
metastasis, usually in the lumbar spine. Only 1 among the 
pleomorphic subtypes presented additional lung metasta-
sis. The patient with lung metastasis died after a less than 
7-month follow-up period.
Follow-up period
The average follow-up period for our patients with lipos-
arcoma was 68.3 months (standard deviation, 47.4 months; 
median, 54.0 months; range, 8-184 months) (Table 1)
2. Anatomical and pathological variables
Tumor size and histology
All patients underwent surgical resection of the tumor. 
Variant myxoid/round-cell represents the most common 
histological type, affecting 13 (52%) of 25 cases. The case 
frequency by histological subtype of liposarcoma was dis-
tributed as follows: 9 (36%) well-differentiated, 13 (52%) 
myxoid/round-cell, and 3 (12%) pleomorphic. Using the 159
CLINICS 2008;63(2):157-64 Prognostic factors and expression of mdm2 in patients with primary extremity liposarcoma
Bispo Júnior RZ et al.
adopted selection criteria, we did not find cases of dediffer-
entiated and mixed liposarcomas.
Concerning histological grade, the selected cases were 
divided into 2 categories: low-grade and high-grade ma-
lignancies, corresponding to 18 (72%) and 7 (28%) cases, 
respectively.
Tumor sizes ranged between 3 and 37 cm (average. 17 
± 9 cm; median, 18 cm) as measured on the specimens after 
surgical resection. Later, the tumors were divided into 3 
groups: < 5 cm (8%), between 5 and 10 cm (20%), and > 10 
cm (72%). (Table 2)
3. Therapeutic variables
Surgical and adjuvant treatment
In all cases, the tumors were subjected to ample resec-
tion according to the Enneking classification.17 Forty-eight 
percent of these patients underwent surgery only.
Thirteen (52%) patients received radiotherapy (RT) 
and/or chemotherapy (ChT) postoperatively. None of them 
received RT and/or ChT followed by surgery. Radiotherapy 
and/or ChT before and after surgery (both) were not insti-
tuted for any of the patients. 
Local recurrence
Local recurrence was observed in 3 (12%) cases, 1 of them 
of the well-differentiated type and 2 of the myxoid/round-cell 
type (1 low-grade malignancy and 1 high-grade malignancy). 
Two low-grade cases presented 2 local recurrences each and 
had no adjuvant therapy. The patient with high-grade neo-
plasia developed only 1 episode of recurrence after receiving 
postoperative radiotherapy. None of the patients experiencing 
local recurrence presented remote metastasis.
Complications of treatment
Eleven (44%) of the 25 treated patients presented com-
plications of 8 types, and some patients presented more than 
one type of associated form. The most frequent complica-
tions were 4 surface infections of the surgical wound, 4 
peripheral nerve injuries, and 3 deep infections.
4. Immunohistochemical variable
mdm2 Expression
Of the 25 cases evaluated for mdm2 protein expression, 
22 (88%) presented positive indexes (≥ 10%) and 3 (12%) 
presented negative indexes (<10%). 
INCLUSION CRITERIA
All patients included in this study met the following 
eligibility criteria: (a) having undergone surgery at IOT for 
local treatment of the primary tumor; (b) having anatomical 
and pathological confirmation of liposarcoma (all slides 
were reviewed by the same pathologist who is an expert in 
Table 1 - Distribution of clinical and epidemiological vari-
ables for the 25 patients with primary liposarcoma of the 
extremities
Variable Category n (%)
Age (years) < 50 
≥ 50
11 (44) 
14 (56)
Sex Male 
Female
11 (44) 
14 (56)
Site Upper limb 
Lower limb
5 (20) 
20 (80)
Side of body Right 
Left
15 (60) 
10 (40)
Delay in seeking medical 
advice (months)
< 24 
≥ 24
12 (48) 
13 (52)
Table 2 - Anatomical and pathological variables—overall survival (OS) at 2.5 and 10 years for the 25 patients with primary 
liposarcomas of the extremities
OS
Variable Category n at 2 years at 5 years at 10 years           P **
Histological subtype Well-differentiated 9 100 (0) 100 (0) 100 (0)
Myxoid/round-cell 13 92 (7) 92 (7) -           0.001
Pleomorphic 3 33 (27) - -
Specimen size (cm) < 5 2 100 (0) 100 (0) -
Between 5 and 10 5 80 (18) 80 (18) 80 (18)           0.759
> 10 18 94 (5) 89 (8) 89 (8)
Grade Low 18 100 (0) 100 (0) 100 (0)           0.003
High 7 71 (17) 57 (19) -
* % values ± standard error; ** P values using the log rank test (Kaplan-Meyer curve)160
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musculoskeletal tissues); and (c) having a tumor located in 
the extremities only, as described in the medical record.
To study the mdm2 nuclear expression marker, we se-
lected the cases for which specimens had been preserved in 
paraffin blocks at the time of biopsy prior to any adjuvant 
therapy, and only primary tumors were included.
EXCLUSION CRITERIA
Patients were excluded from the study if they (a) pre-
sented metastases and/or local recurrence during the first 
evaluation; (b) had postoperative follow-up periods of less 
than 2 years, except for those who died of cancer before that   
period; (c) underwent any treatment prior to enrollment at 
IOT.
ASSESSMENT OF IMMUNOHISTOCHEMICAL 
POSITIVITY
The mdm2 protein was classified as present or absent. 
For the immunohistochemical analysis, the tumors were 
classified as positive (positivity ≥ 10% of the sample) or 
negative (Figure 1).
Protein expression was assessed at 400x magnification, 
and the nuclei with unequivocally typical brown immuno-
expression were considered positive. At least 400 nuclei of 
neoplastic cells were counted per case.
STATISTICAL ANALYSIS
The descriptive analysis of the sample was performed 
based on average, median, and percentage values. The 
simple frequencies of all variables studied were calculated. 
The accumulated survival probabilities were evaluated us-
ing the Kaplan-Meier method, and the survival curves were 
compared using the log rank test.
Positive or negative indexes for mdm2 were evaluated as 
variables to determine their prognostic value and the value 
of the association with other (anatomical and pathological) 
variables. The associations were performed according to 
Fisher’s exact test.
The rounding up of frequency and survival rates was used 
to simplify calculations. Statistical significance was defined 
for P values < 0.05.
RESULTS
The prognostic value of some important clinical, epide-
miological, anatomical, pathologic, and immunohistochemi-
cal variables was also evaluated based on curves of local 
recurrence-free survival, metastasis-free survival, and overall 
survival.
Prognostic factors related to local recurrence-free 
survival
Male gender (P = 0.023) was considered an adverse 
factor; the pleomorphic subtype (P = 0.027) presented the 
highest index of local recurrence. High histological grade 
(P = 0.007) had the worst prognosis. The other factors 
investigated (age, site, side of body, delay in seeking medi-
cal advice, specimen size, or type if treatment performed) 
did not reach statistically significant levels. The presence 
or absence of mdm2 did not reach statistically significant 
levels and was not considered a prognostic factor for local 
recurrence-free survival. 
Prognostic factors related to metastasis-free survival
Age less than 50 years (P = 0.040), male sex (P = 0.040), 
pleomorphic subtype (P < 0.001), and high histological 
grade (P = 0.003) were considered adverse factors for me-
tastasis-free survival (Figure 2). The other factors studied did 
not reach statistically significant levels (site, side of body, 
delay in seeking medical advice, specimen size, and type 
of treatment performed). Immunohistochemical evidence of 
the presence or absence of mdm2 gene expression did not 
reach statistically significant levels and was not considered 
a prognostic factor for metastasis-free survival. 
Prognostic factors related to overall survival
The overall survival curve for the 25 patients is shown 
in Figure 3. Age under 50 years (P = 0.036), male sex (P = 
0.043), pleomorphic subtype (P = 0.001), and high histologi-
Figure 1 - Photomicrograph showing a positive immunohistochemical result 
for the presence of mdm2 protein (magnification 400 x)161
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Figure 3 - Curve depicting overall survival (years) for the 25 patients with liposarcoma of the extremities
Figure 2 - Curve depicting metastasis-free survival (years) for the 25 patients with liposarcoma of the extremities according to the histological grade
cal grade (P = 0.003) were also considered adverse factors. 
Site, side of body, delay in seeking medical advice, specimen 
size, and type of treatment performed did not reach statistical-
ly significant levels. Also, the presence or absence of mdm2 
protein expression did not influence the overall survival. 
Analysis of the correlation between mdm2 protein 
expression and anatomical and pathological variables
As shown in Table 3, there was no statistically significant 
association between the expression (or not) of mdm2 pro-
tein and the following anatomical and pathological variables: 
subtype, grade, and size of tumors.
DISCUSSION
Although there are more than 30 histological types of 
soft tissue sarcomas, many of them are grouped for being 
similarly diagnosed, staged, and treated.18 However, because 
these sarcomas include a large series of histological types, 
the clinical course of each type of sarcoma can be extremely 
different.2
Soft tissue sarcomas account for less than 1% of all ma-
lignant tumors.19 As shown in many publications,19-24 of this 
percentage, between 10% and 20% are liposarcomas, which 
are considered the second most frequent type.20,23
Concerning global survival, Reitan et al5 asserted that 
younger patients presented better prognoses, which does 
not agree with our findings, where we found a significant 
difference regarding worse prognosis for patients under 50 
years of age.
A few investigators have asserted that the most common 
form of liposarcoma is the well-differentiated sarcoma.25 
The most frequent histological type found in our study was 162
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the myxoid/round-cell type (52%), in agreement with other 
current studies.23,26
One of the most important factors influencing the sur-
vival rate seems to be the histological type of the tumor. In 
our case series, we found that the histological subtype of 
liposarcoma is significantly related with survival; that is, 
patients with pleomorphic liposarcoma are at higher risk 
for death than those who have myxoid/round cell or well-
differentiated sarcomas. We also observed a significant risk 
of local recurrence and development of remote metastases 
and worse prognosis for patients with the pleomorphic his-
tological type.
Tumor grade has been clearly recognized as a perfor-
mance predictor, with high-grade tumors being associated 
with prognoses that are unfavorable for survival.27 For li-
posarcomas of the extremities, this also appears to be the 
case.2
The high average value of tumor size seems to be di-
rectly related to the long evolution time presented by these 
neoplasias. However, in this series, we did not find that the 
dimension of the tumor was a prognostic factor in any of the 
surviving patients studied.
As a group, liposarcomas present a postoperative lo-
cal recurrence rate of approximately 50%. However, these 
indexes are lower if only injuries of the extremities are 
considered.28.29 In our case series, of the 25 patients under-
going ample surgical resection, 3 presented local recurrence 
during the follow-up period: 1 of the well-differentiated 
type and 2 of the myxoid/round-cell type (1 low-grade and 
1 high-grade).
mdm2 gene amplification has been shown to occur at a 
high frequency in many studies on soft tissue sarcomas. The 
product of mdm2 interacts with the p53 protein and inhibits 
its ability to regulate genetic expression as a transcription 
factor. Thus, amplification (and subsequent overexpression) 
of mdm2 may have the same effect as that of mutations in 
p53.30
The changes in the mdm2 gene are known to be a 
common mechanism in the genesis of liposarcomas.31 The 
amplification of this gene and its mRNA overexpression 
can lead to overproduction of mdm2 protein.32 The im-
munohistochemical analysis reveals nuclear location and 
overexpression of mdm2 in these tumors with amplification 
of the mdm2 gene.33
In liposarcomas, amplification of the mdm2 gene is 
observed only in high-frequency well-differentiated tumors, 
not in other tumor subtypes.32 Another author34 mentions 
that amplification of the mdm2 gene is not also seen in 
myxoid liposarcomas, the largest subtype of sarcomas. On 
the other hand, Schneider-Stock et al31 found amplification 
of the mdm2 gene in the myxoid and pleomorphic variants, 
although the well-differentiated liposarcoma is characterized 
by an already known high frequency.
Although immunohistochemistry can be used to demon-
strate mdm2 overexpression, direct correlation between the 
gene amplification and protein overexpression is not the rule.35 
Nevertheless, mutations cause an irregular increase in stable 
proteins that can be detected by immunohistochemistry.36
In our case series, immunohistochemistry showed mdm2 
protein expression in 22 (88%) of the 25 cases. Of these 22 
cases, 7 (32%) were of the well-differentiated subtype, 12 
(54.5%) of the myxoid/round-cell type, and 3 (13.5%) of 
the pleomorphic type. Data from this study indicate a high 
frequency of the presence of mdm2 protein in the different 
histological subtypes of liposarcomas, suggesting preliminar-
ily a high sensitivity of this marker in this pathology. In spite 
of this, currently, the diagnosis of these neoplasms is based 
on morphology, not immunocytochemical tests.
Table 3 - Study of the correlation between the immunohistochemical evidence of mdm2 expression and the anatomical and 
pathological variables in the 25 patients with primary liposarcoma of the extremities
Variable Category n
MDM2
P* Negative Positive
n = 3 n = 22
Histological subtype Well-differentiated 9 2 (67%) 7 (32%)
Myxoid/Round Cell 13 1 (33%) 12 (55%) 0.695
Pleomorphic 3 0 (0%) 3 (14%)
Specimen size (cm) < 5 2 0 (0%) 2 (9%)
Between 5 and 10 5 0 (0%) 5 (22%) 1.000
> 10 18 3 (100%) 15 (68%)
Grade Low 18 2 (67%) 16 (73%) 1.000
High 7 1 (33%) 6 (27%)
* P values using Fisher’s exact test163
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CONCLUSIONS
1) There was no correlation between the mdm2 protein 
expression as observed by immunohistochemistry and the 
anatomical and pathological variables studied; additionally, 
there was no relationship between those variables and the 
different prognostic factors in primary liposarcomas of the 
extremities. 2) Factors such as male sex, pleomorphic histo-
logical subtype, and high grade of malignancy are unfavor-
able for local recurrence-free survival. 3) Factors such as 
male sex, age under 50 years, pleomorphic subtype, and high 
histological grade are adverse for metastasis-free survival 
and overall survival. 4) mdm2 expression was a frequent 
event in the different subtypes of liposarcomas.
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